Lynda Schneider, MD

Lynda Schneider, MD

Director, Allergy Program

Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-6117

  • Fax: 617-730-0310

Medical Services

Specialties

  • Allergic Rhinitis
  • Anaphylaxis
  • Asthma
  • Atopic Dermatitis
  • Eczema
  • Food Allergy
  • Immunotherapy

Departments

  • Allergy Immunology
  • Medicine

Languages

  • English

Programs

  • Allergy Program
  • Atopic Dermatitis Center
  • Immunology Program
  • Primary Immunodeficiency Disorders Program
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Experience and Education

Education

Undergraduate

Pennsylvania State University, 1979

University Park, PA

Medical School

Jefferson Medical College, 1983

Philadelphia, PA

Internship

Massachusetts General Hospital, 1983-1984

Boston, MA

Residency

Massachusetts General Hospital, 1984-1987

Boston, MA

Fellowship

Boston Children's Hospital, 1987-1989

Boston, MA

Certifications

  • Allergy/Immunology, Pediatrics, Diagnostic Laboratory Immunology

Research

Lynda Schneider is engaged in evaluating new therapies for allergic diseases through clinical trials.  Current trials focus on evaluating a multidisciplinary approach to caring for children with atopic dermatitis (AD), exploring the genetics and phenotypes of patients with AD, and oral immunotherapy and epicutaneous immunotherapy for peanut-allergic children.

Throughout the 1990s, Dr. Schneider and colleagues evaluated new treatments for atopic dermatitis, including interferon-gamma, topical tacrolimus, and pimecrolimus.  They also studied the use of anti-IgE for food allergy and C1-inhibitor for hereditary angioedema.  Other projects have included the use of intravenous immunoglobulin for asthma as well as anti-IgE for asthma.

Her current projects focus on testing ways to reverse food allergies by re-training the immune system to tolerate foods.  These trials include, the PRROTECT Study, a trial that explores the use of omalizumab (anti-IgE) in oral immunotherapy for peanut-allergic children and the PEPITES Study, a phase III trial to assess efficacy and safety of peanut epicutaneous immunotherapy in peanut-allergic children.  Dr. Schneider also received funding by the National Institute of Health as a site for the Atopic Dermatitis Registry Network: Clinical Studies Consortium.

Professional History

About Lynda Schneider

Lynda Schneider received her MD from Jefferson Medical College.  She completed an internship and residency at Massachusetts General Hospital and a postdoctoral fellowship at Boston Children’s Hospital.  Dr. Schneider received the 2004 AAAAI/Aventis Women in Allergy Project Grant Award.  In 2009, she served as a member of the NIH Food Allergy Clinical Guideline Expert Panel.  In 2011, she was the Chair on the Atopic Dermatitis Practice Parameter Workgroup.


Key Publications

  • Chou JS, LeBovidge J, Timmons K, Elverson W, Morrill J, Schneider LC.  Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment.  Allergy Asthma Proc.  2011 Sept; 32(5):377-383, doi: 10.2500/aap.2011.32.3462

 

  • Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut allergic patients. J Allergy Clin Immunol.  2013;6:1368-1374. doi: 10.1016/j.jaci.2013.09.046. Epub 2013 Oct 28. PMID: 24176117

 

  • LeBovidge JS, Haskell S., Olney EK, Hoyte L, Rachid R, Nadeau K, Umetsu D, Schneider, LC. The Psychological Impact of Oral Immunotherapy for Children with Food Allergy: Perceived Benefits and Treatment Burden. Clinical Practice in Pediatric Psychology.  2014;2(1):13-26. doi: 10.1037/cpp0000053

 

  • Schneider L, Hanifin JM, Boguniewicz M,  Eichenfield, LF, Spergel J, Dakovic R, Paller AS. Study of the Atopic March: Development of Atopic Co-Morbidities.  Pediatric Dermatology. 2016.

To schedule an appointment: Call 617-355-6117 or Request an Appointment

Locations

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close